New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:14 EDTGALEGalena presents GALE-301 Phase 1 data
Galena announced that data from the company's Phase 1 study with GALE-301, or Folate Binding Protein, was presented at the American Society of Clinical Oncology 50th Annual Meeting. The poster entitled, "Comparison of recurrent and nonrecurrent ovarian and uterine cancer patients undergoing adjuvant folate receptor vaccine therapy," was presented during the Gynecologic Cancer General Poster Session. Overall, 30 patients were enrolled in the Phase 1 trial. Of 14 control patients, 50% have recurred. Of 16 vaccinated patients, 25% have recurred after completing the primary vaccine series and 12.5% recurred prior to completing the PVS, and one patient withdrew. Of note, no recurrences have been seen in the optimal dose cohort of 1000 mcg E39. The vR patients displayed lower mean delayed type hypersensitivity reactions as well as lower local reactions at every measured time point. The company said, "These promising initial results demonstrate the vaccine is dose responsive with the immune system and we are encouraged about the potential for this compound to prevent recurrence in women suffering from high risk gynecological cancers where current treatment options are limited. The data from this study served as the basis for advancing GALE-301 into its ongoing Phase 2 trial that includes a booster regimen. We expect enrollment in this trial to complete shortly, ahead of schedule."
News For GALE From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 25, 2014
18:21 EDTGALEOn The Fly: After Hours Movers
Subscribe for More Information
17:59 EDTGALEGalena announces release of special committee report regarding stock promotion
Galena Biopharma announced the release of a report prepared by the former Special Committee of Galena's board regarding the company's 2012-2014 market visibility campaigns and the sale of shares by insiders in Q1. Some of the findings from the report include: "We found no evidence that, with the exception of Mark Ahn, insiders had knowledge of Dream Team Group's activities before trading in the company 's stock; We found no evidence that officers and directors had material nonpublic information before trading in the company's stock; We found no evidence that the trades by officers and directors in 1Q14 violated company policy; During our investigation, we discovered that another of the company's investor relations firms, Lidingo Holdings, might have engaged in improper conduct relative to the payment of bloggers for promotional articles written about the company; We found that Mark Ahn granted stock options to Lidingo as part of its compensation for its services without Board approval, which is contrary to company policy; Based on these findings of fact, we conclude that it is possible that Lidingo violated Section 17b of the Securities Act of 1933." Shares of Galena are up 6% after hours following the release of the special committee report. Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use